FULC Stock Forecast & Price Target

Fulcrum Therapeutics is currently in a phase of strategic review with a strong cash position of $333 million, demonstrating prudent financial management decisions. The company has a promising product in Pociredir, which has shown positive clinical data in its Phase 1b trial for sickle cell disease. With the potential for a corporate transaction on the horizon, the company's focus on reducing OpEx and potential for future product acquisitions or a merger, make it an attractive prospect for investors.

Fulcrum Therapeutics is facing significant challenges, as the FDA has discontinued the development of its oral small molecule Pociredir for sickle cell disease due to concerns about potential secondary hematologic malignancies. This decision follows the FDA's previous withdrawal of another PRC2 inhibitor, Tazverik, from the market in March 2026 due to similar concerns. Despite efforts to demonstrate the differences between Pociredir and Tazverik, the FDA has taken a broad stance and sees any PRC2 inhibition as carrying a similar risk. The discontinuation of Pociredir will require Fulcrum to find alternative strategic plans and may lead to a substantial reduction in operating expenses.